Mouse myeloma cell line NS0-derived recombinant human NKp30/NCR3 Leu19-Thr138 Accession # Q05D23
Specificity
Detects human NKp30/NCR3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 5% cross‑reactivity with recombinant human (rh) NKp80, rhNKp44 and rhNKp46 is observed.
Source
N/A
Isotype
IgG
Clonality
Polyclonal
Host
Goat
Gene
NCR3
Purity Statement
Antigen Affinity-purified
Innovator's Reward
Test in a species/application not listed above to receive a full credit towards a future purchase.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Preservative
No Preservative
Concentration
LYOPH
Reconstitution Instructions
Reconstitute at 0.2 mg/mL in sterile PBS.
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for NKp30/NCR3 Antibody
Activating natural killer receptor p30
CD337 antigen
CD337
CD337activating NK-A1 receptor
LY117,1C7NK-p30
lymphocyte antigen 117
natural cytotoxicity triggering receptor 3
Natural killer cell p30-related protein
NCR3
NKp30
NKp30MALS
Background
NKp30, along with NKp44 and NKp46, constitute a group of receptors termed “Natural Cytotoxicity Receptors” (1). These receptors play a major role in triggering NK‑mediated killing of most tumor cells lines. NKp30 is a type I transmembrane protein having a single extracellular V-like immunoglobulin domain (2). A physical association with the ITAM-bearing accessory protein, CD3 zeta , occurs via a charged residue in the NKp30 transmembrane domain. Ligation of NKp30 with a specific antibody results in phosphorylation of CD3 zeta (3). NKp30 is expressed on both resting and activated NK cells of the CD56dim, CD16+ subset that account for more that 85% of NK cells found in peripheral blood and spleen (4). NKp30 is absent from the CD56bright, CD16- subset that constitutes the majority of NK cells in lymph node and tonsil, however, its expression is up‑regulated in these cells upon IL-2 activation (4). Studies with neutralizing antibodies reveal that NKp30 is partially responsible for triggering lytic activity against several tumor cell types and that it is the main receptor responsible for NK‑mediated lysis of immature dendritic cells (2, 5). The ligand(s) recognized by NKp30 has not been described.
Moretta, L. and A. Moretta (2004) EMBO J. 23:255.
Pende, D. et al. (1999) J. Exp. Med. 190:1505.
Augugliaro, R. et al. (2003) Eur. J. Immunol. 33:1235.
Ferlazzo, G. et al. (2004) J. Immunol. 172:1455.
Ferlazzo, G. et al. (2002) J. Exp. Med. 195:343.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
=
÷
Review this Product
Be the first to review our NKp30/NCR3 Antibody and receive a gift card or discount.